

**Martin A. Hay & Co.**

13 Queen Victoria Street  
Macclesfield  
Cheshire SK11 6LP  
UNITED KINGDOM

Tel: (+44) 1625 500057  
Fax: (+44) 1625 500058

E-mail: martinahay@martin-a-hay.com

**RECEIVED**  
**CENTRAL FAX CENTER**

SEP 19 2005

**FACSIMILE TRANSMITTAL SHEET**

---

**Date:** 19 September 2005 **Total Number of Pages:** 10  
(including cover page)

**To:** Attn: Group Art Unit 1626  
USPTO

**FAX Number:** 001 703 872 9306

**From:** Martin A Hay

**FAX Number:** (44) 1625 500058

**Acknowledgment Requested:** Yes No

**Message:**

**Re:** Appln Serial No 10/508,941  
Applicants: Han, Zhengxu et al  
Our Ref: 00314/US1

**Response to Office Communication of August 22, 2005.**

---


**NOTE:**

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please telephone (44) 1625 500057 collect.

---

RECEIVED  
CENTRAL FAX CENTER

SEP 19 2005

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
MARTIN A. HAY	
Type or print name of person signing certification	
	9/19/05
Signature	Date

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : HAN, ZHENGXU  
: KRISHNAMURTHY, DHILEEPKUMAR  
: SENANAYAKE, CHRIS HUGH  
: LU, ZHI-HUI  
Assignee : Apsinterm, LLC  
Serial No. : 10/508,941  
Filed : March 2, 2005  
For : Method of Preparing Amine Stereoisomers  
Art Unit : 1626  
Examiner : Freistein, Andrew B.  
Docket No. : 00314/US1  
Customer No. : 024330  
Confirm No. : 7558

Commissioner for Patents  
P.O. Box 1450  
Alexandria  
VA 22313-1450  
United States

Sir:

Serial No. 10/508,941  
Response to Office Communication of August 22, 2005

- 2 -

This communication is being filed in response to the Office Communication of August 22, 2005.

**Restriction under 35 U.S.C. § 121 and 375**

The Examiner requires restriction of the application to one of the following Groups of inventions:-

Group I: Claims 1 to 32  
Group II: Claims 33 and 38  
Group III: Claims 39-42  
Group IV: Claims 43 to 45

Applicants hereby elected to prosecute the invention of Group I, Claims 1 to 32. The election is made without traverse.

**Election of Species under 37 C.F.R. 1.146**

The Examiner has requested the election of a single compound.

It is understood that the Examiner is requiring a election of species of the invention under 37 C.F.R. 1.146, and that the examination will only be restricted to this species if no claim to the genus is found to be allowable.

Although Applicants have described their invention primarily with respect to a process for making stereoisomers of the compound sibutramine, it is respectfully submit that they have actually invented a general process for preparing amine stereoisomers. The terms used in Claim 1 are believed to properly define this process. In this connection, the Examiner's attention is drawn to co-pending application serial number 10/120,541, cited in Applicant's information disclosure statement, which claims a related process invention in broad

Serial No. 10/508,941

Response to Office Communication of August 22, 2005


- 3 -

terms. This related invention has been searched broadly by the Examiner handling it. Applicants very much hope that it will prove possible for the Examiner to conduct a similarly broad search in the present application.

Applicants hereby elect the species of the invention described generally in Scheme 6 on pages 36 to 37 and specifically in Example 5.16 and Scheme 13, on pages 50 to 51. This scheme depicts a process for preparing the amine stereoisomer (R)-didesmethylsibutramine, which could be alkylated to afford (R)-sibutramine (see formulae in Schemes 1 and 2 on page 2).

Referring to Schemes 6 and 13 and to Claim 1, the process described in Schemes 6 and 13 maps to Claim 1 as follows:-

A method of preparing an amine stereoisomer:-



(R)-didesmethylsibutramine.

which comprises stereoselectively reducing:-


using e.g. NaBH<sub>4</sub> as reducing agent

a sulfinylimine:-


Serial No. 10/508,941

Response to Office Communication of August 22, 2005


- 4 -



that bears on the sulfinyl group a residue of an alcohol:-



to afford a sulfonamide stereoisomer:-




followed by contacting the sulfonamide stereoisomer with a reagent suitable for the cleavage of a sulfur-nitrogen bond:-  
an acid, e.g. HCl

Serial No. 10/508,941

Response to Office Communication of August 22, 2005

- 5 -

to afford an amine stereoisomer:-



It may be helpful to the Examiner to appreciate that in the elected species and generally in preferred embodiments of the invention, the invention effectively makes use of the stereochemistry in a beta-amino alcohol stereoisomer to set the stereochemistry in an amine product. The process proceeds via a chiral 1,2,3-oxathiazolidine-S-oxide. If the Examiner looks at a formula for a 1,2,3-oxathiazolidine-S-oxide (e.g. formula 3 on page 29), he will see that the oxa and aza parts are derived from the hydroxy and amino parts of the beta-amino alcohol.

The following dependent claims 2 to 30 also read on the elected species:-

- 2 - sulfinylimine is a sulfinylimine stereoisomer
- 3 - residue of alcohol is in stereoisomeric form
- 4 - residue of an alcohol is residue of an N-substituted beta-amino alcohol
- 5 - alcohol maps to formula in wherein A<sub>1</sub> is -L-R<sub>7a</sub> in which -L- represents -SO<sub>2</sub>- and R<sub>7a</sub> represents substituted aryl (p-toluene), A<sub>2</sub> is O, R<sub>8</sub> is hydrogen, R<sub>9</sub> is phenyl, R<sub>10</sub> is hydrogen and R<sub>11</sub> is hydrogen

Serial No. 10/508,941

Response to Office Communication of August 22, 2005

- 6 -

6 - A<sub>2</sub> is O

7 - R<sub>8</sub> is hydrogen, R<sub>9</sub> is phenyl, R<sub>10</sub> is hydrogen and R<sub>11</sub> is hydrogen

8 - R<sub>7</sub> is -SO<sub>2</sub>-R<sub>7a</sub> in which R<sub>7a</sub> is (6-10C)aryl (phenyl) substituted by (1-4C)alkyl (methyl).

9 - R<sub>7</sub>N is residue of an optionally N-substituted 1-amino-1-phenyl-2-methyl-2-propanol

10 - sulfinylimine has been prepared by contacting an iminometal (with a 1,2,3-oxathiazolidine-S-oxide - see scheme 8 and Example 5.8.1 on pages 41-42

11 - 1,2,3-oxathiazolidine-S-oxide is a compound of formula 3 wherein A<sub>1</sub> is -L-R<sub>7a</sub> in which -L- represents -SO<sub>2</sub>- and R<sub>7a</sub> represents substituted aryl (p-toluene), A<sub>2</sub> is O, R<sub>8</sub> is hydrogen, R<sub>9</sub> is phenyl, R<sub>10</sub> is hydrogen and R<sub>11</sub> is hydrogen

12 - 1,2,3-oxathiazolidine-S-oxide is the first of the depicted stereoisomers

13 - amine stereoisomer is a compound of formula 5 in which R<sub>5</sub> and R<sub>6</sub> are each substituted alkyl and R<sub>12</sub> and R<sub>13</sub> are each hydrogen

14 - A<sub>2</sub> is O

15 - R<sub>5</sub> and R<sub>6</sub> are each substituted alkyl, the 1,2,3-oxathiazolidine-S-oxide is a compound of formula 3, and the sulfinylimine stereoisomer is of formula 4.

Serial No. 10/508,941

Response to Office Communication of August 22, 2005

- 7 -

- 16 -  $R_{12}$  and  $R_{13}$  are both hydrogen
- 17 - 1,2,3-oxathiazolidine-S-oxide has been prepared by reacting an optionally N-substituted beta-amino alcohol (N-tosyl-1-amino-1-phenyl-2-methyl-2-propanol) with a thionyl halide (thionyl chloride) - see e.g. scheme 3 on page 32
- 18 -Amine stereoisomer product of elected process species could be alkylated to afford sibutramine (see structure on page 2).
- 19 - amine stereoisomer is covered by formula 7
- 20 - amine stereoisomer is covered by formula 14
- 21 -  $R_{15}$  and  $R_{16}$  are both hydrogen
- 22 - metal imine is as depicted
- 23 - 1,2,3-oxathiazolidine-S-oxide is first depicted formula
- 24 - sulfinylimine is reduced using a hydride reducing agent (e.g.  $\text{NaBH}_4$ )
- 25 - hydride reducing agent is  $\text{NaBH}_4$
- 26 - cleavage reagent is an acid ( $\text{HCl}$ )
- 27 - acid is  $\text{HCl}$



Serial No. 10/508,941

Response to Office Communication of August 22, 2005


- 9 -

be allowable. In this connection, it is respectfully submitted that the present invention provides a process for preparing amine stereoisomers in general, and that the generic claims progressively further define the features of this process. It is very much hoped that the Examiner will be able to extend his search beyond a process for making (R)-didesmethylsibutramine to a process for making amine stereoisomers generically as in claim 1 or at least as in one of the dependent generic claims.

**Communication by Telephone**

The undersigned's office is located in the United Kingdom, and hence the Examiner may have difficulty contacting him from the USPTO by telephone. If the Examiner wishes to speak with the undersigned by telephone, he can contact the undersigned by e-mail at martinahay@martin-a-hay.com.

Respectfully submitted,

  
Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

e-mail: martinahay@martin-a-hay.com

Customer No. 024330

[Martin A. Hay &amp; Co.,

13 Queen Victoria Street

Macclesfield

Cheshire

SK11 6LP

UNITED KINGDOM]

September 19, 2005